---|---------|----------|-------------| | Wegovy Pill | Novo | Approved 2025 | 16% | | CagriSema | Novo | 2026 | ~25% | | Orforglipron | Lilly | Late 2026 | 12-14% | | Retatrutide | Lilly | 2027-2028 | 28.7% | | Amycretin | Novo | 2027-2028 | 24%+ | | Survodutide | BI | 2027+ | ~20% |
The Bottom Line
The current generation (semaglutide, tirzepatide) is effective. The next generation promises: - 25-30% weight loss (vs. 15-22% now) - More oral options - Better muscle preservation - More specialized targeting
For men considering GLP-1s today: start now with available medications. Stay informed about pipeline drugs. Be ready to switch or augment as better options emerge.
The field is moving fast. The best is yet to come — but "good enough to change your life" is available today.
Related Articles: - GLP-1 Medications for Men: The Complete 2026 Guide - Oral Wegovy Just Launched: The Injection-Free Era Begins - The BELIEVE Trial: 92.8% of Weight Loss Can Be Fat
Last updated: January 2026
Medical disclaimer: This content is for informational purposes only. Pipeline drugs are not yet approved.